Name: Mesoblast (MSB) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

MSB

Pharmaceuticals, Biotechnology & Life Sciences

Mesoblast

Short interest: 7.77%; +0.50 pp 30d; as of 9 Oct 2026
Reported shorts: 100.9M
Shares on issue: 1.299B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Mesoblast

Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular medicines at scale.

Company profile →

Mesoblast (ASX:MSB) has 7.77% of its shares on issue reported as short positions as of 9 Oct 2026, or about 100,903,060 shares. Over the past 30 days that figure has risen 0.50 percentage points, and over 90 days it has fallen 0.34 percentage points. Its highest recorded short interest was 11.00% in October 2015. MSB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads MSB today

Zanger BreakoutWatchScore 34rank 385 of 1893
CAN SLIMWatchScore 19rank 757 of 1549
Minervini Trend TemplateWatchScore 9rank 1379 of 1684
Crowded-Short BreakoutSetupScore 41rank 38 of 1448
Quality compoundersWatchScore 19rank 792 of 1660

Prices to 15 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

MSB fundamentals

In the year to 30 Jun 2026, Mesoblast (ASX:MSB) recorded revenue of US$120.3M and a net loss after tax of US$57.5M. A year earlier it recorded revenue of US$17.2M and a net loss after tax of US$102.1M. Net margin −47.8%, return on equity −9.9% (FY). Figures are in USD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →